The article highlights Scholar Rock Holding Corporation as a top small-cap healthcare stock, focusing on its innovative treatments for severe diseases. The upcoming Phase 3 trial results could significantly impact its value. Hedge funds are showing interest, with potential for a 201.08% increase in stock value.